News

Emalex Biosciences announced the closing of an upsized and oversubscribed $250 million Series D funding round that will fund a Phase 3 clinical trial and potential commercialization of…
Read More...

Ascletis Pharma Inc. announces that the Investigational New Drug (IND) application of ASC11, an oral inhibitor drug candidate targeting 3-chymotrypsin like protease (3CLpro) for…
Read More...

Amneal Pharmaceuticals, Inc. announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (“FDA”) for leuprolide acetate…
Read More...

Novo Holdings, a leading healthcare investment firm, announced today its acquisition of KabaFusion, a leading national provider of home infusion therapies, from Pritzker Private Capital…
Read More...

PharmaTher Holdings Ltd., a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and…
Read More...

CSL Limited announces that its subsidiary, CSL Seqirus, has entered into a collaboration and license agreement with Arcturus Therapeutics Holdings Inc (“Arcturus Therapeutics”) to…
Read More...

Exelixis, Inc. and Sairopa B.V. announced that the companies have entered into an exclusive clinical development and option agreement for ADU-1805, a potentially best-in-class…
Read More...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat…
Read More...

Almirall, S.A. (ALM) announced that the European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for lebrikizumab for the treatment of…
Read More...

Biofrontera Inc. announced it has entered into private exchange agreements with certain holders of options to acquire ordinary shares of Biofrontera AG (the “AG Options”) in exchange…
Read More...

Thermo Fisher Scientific Inc. announced that it has entered into a definitive agreement to acquire The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics,…
Read More...

InnoCare Pharma announced that the first adolescent patient has been dosed in clinical trial with its second generation pan-TRK inhibitor ICP-723 at the Sun Yat-sen University Cancer…
Read More...

Karyopharm Therapeutics Inc. and the Menarini Group announced that the European Commission (EC) has granted orphan medicinal product designation for selinexor for the treatment of…
Read More...

Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders, and Phoenix Biotech Acquisition…
Read More...

Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DYNE-251 for the treatment of Duchenne muscular dystrophy (DMD)…
Read More...

Roche announced positive topline results from two global phase III studies, BALATON and COMINO, evaluating the first and only bispecific antibody for the eye, Vabysmo (faricimab), in…
Read More...

Outlook Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for filing a Biologics License Application (BLA) for ONS-5010 / LYTENAVA…
Read More...

AbbVie announced that the European Medicines Agency (EMA) has validated a Marketing Authorization Application (MAA) for epcoritamab (DuoBody-CD3xCD20), an investigational subcutaneous…
Read More...

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat…
Read More...

Telix announces a collaboration with UniQuest Pty Ltd (UniQuest), the commercialisation company of The University of Queensland (UQ), to develop a radiolabelled molecule targeting an…
Read More...